- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis
This study is testing a new medicine called GLPG3667 for adults with dermatomyositis. We want to see if it helps improve their condition, if it's safe to use, and how the body handles it. Participants will take either the medicine or a dummy pill for 24 weeks.
For: dermatomyositisGermany · Italy · Romania - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.
This study is testing a new medicine called GLPG3667 for adults with active lupus (SLE). Researchers want to see if it helps reduce lupus symptoms, if it's safe, and how the body handles it. Some people will get the medicine, and others will get a dummy pill.
For: Systemic Lupus ErythematosusGermany · France · Spain